TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT03128489

Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants

Cause of deathSafety Automatic label, confidence 0.9, unverified. How labels are made.
“The study is cancelled due to reassessment of the medical need for the vaccine in India. Cancellation is not related to vaccine's safety and/or efficacy.”

The sponsor’s own words in the registry.

Life of this trial

201720182019Registered2017-04-20Planned start2017-12-01 (planned)Withdrawn (as of)2017-12-26

Vital statistics

Status
Withdrawn
Phase
Phase 3
Sponsor
GlaxoSmithKline
Sponsor type
Industry
Conditions
Diphtheria; Acellular Pertussis; Haemophilus Influenzae Type b; Tetanus; Poliomyelitis
Interventions
Infanrix-IPV/Hib
Participants
0

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.